TransThera Gets US FDA Fast Track Designation for Prostate Cancer Drug; Shares Up 3%

MT Newswires Live

2025/06/24

TransThera Sciences (HKG:2617) said the US Food and Drug Administration has granted fast-track designation for tinengotinib to treat metastatic castration-resistant prostate cancer (mCRPC), according to a Tuesday Hong Kong bourse filing.

In a phase 1/2 study, the drug showed a 46% objective response rate and 85% disease control rate among 13 mCRPC patients with measurable disease, the filing said.

TransThera said the latest designation reflects consistent clinical execution and supports further development of the drug for advanced prostate cancer.

Shares of the clinical-stage biopharmaceutical firm rose about 3% in recent trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545778427"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545778427\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545778427?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 10:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545778427","market":"nz","top_or_hot":-1,"title":"TransThera Gets US FDA Fast Track Designation for Prostate Cancer Drug; Shares Up 3%","media":"MT Newswires Live","content":"<html><body><p> TransThera Sciences (HKG:2617) said the US Food and Drug Administration has granted fast-track designation for tinengotinib to treat metastatic castration-resistant prostate cancer (mCRPC), according to a Tuesday Hong Kong bourse filing.</p><p>In a phase 1/2 study, the drug showed a 46% objective response rate and 85% disease control rate among 13 mCRPC patients with measurable disease, the filing said.</p><p>TransThera said the latest designation reflects consistent clinical execution and supports further development of the drug for advanced prostate cancer.</p><p>Shares of the clinical-stage biopharmaceutical firm rose about 3% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransThera Gets US FDA Fast Track Designation for Prostate Cancer Drug; Shares Up 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransThera Gets US FDA Fast Track Designation for Prostate Cancer Drug; Shares Up 3%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-06-24 10:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> TransThera Sciences (HKG:2617) said the US Food and Drug Administration has granted fast-track designation for tinengotinib to treat metastatic castration-resistant prostate cancer (mCRPC), according to a Tuesday Hong Kong bourse filing.</p><p>In a phase 1/2 study, the drug showed a 46% objective response rate and 85% disease control rate among 13 mCRPC patients with measurable disease, the filing said.</p><p>TransThera said the latest designation reflects consistent clinical execution and supports further development of the drug for advanced prostate cancer.</p><p>Shares of the clinical-stage biopharmaceutical firm rose about 3% in recent trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4104","symbol_name":"貿易公司與經銷商","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2545778427","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545778427","pubTimestamp":1750730465,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TransThera Sciences  said the US Food and Drug Administration has granted fast-track designation for tinengotinib to treat metastatic castration-resistant prostate cancer , according to a Tuesday Hong Kong bourse filing.In a phase 1/2 study, the drug showed a 46% objective response rate and 85% disease control rate among 13 mCRPC patients with measurable disease, the filing said.TransThera said the latest designation reflects consistent clinical execution and supports further development of the drug for advanced prostate cancer.Shares of the clinical-stage biopharmaceutical firm rose about 3% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4104":"贸易公司与经销商","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","FAST":"快扣","BK4588":"碎股","BK4567":"ESG概念","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK4585":"ETF&股票定投概念","02617":"药捷安康-B"},"translate_title":"TransThera获得美国FDA前列腺癌药物快速通道指定；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FAST":1,"02617":0.9},"content_text":"TransThera Sciences (HKG:2617) said the US Food and Drug Administration has granted fast-track designation for tinengotinib to treat metastatic castration-resistant prostate cancer (mCRPC), according to a Tuesday Hong Kong bourse filing.In a phase 1/2 study, the drug showed a 46% objective response rate and 85% disease control rate among 13 mCRPC patients with measurable disease, the filing said.TransThera said the latest designation reflects consistent clinical execution and supports further development of the drug for advanced prostate cancer.Shares of the clinical-stage biopharmaceutical firm rose about 3% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}